Simon Lowry, MD,
WALTHAM, Mass. and SHANGHAI, China, Sept. 07, 2022 (GLOBE NEWSWIRE) — Zenas BioPharmaa global biopharmaceutical company committed to becoming a leader in the development and commercialization of immune therapies for patients in need around the world, today announced the appointment of Simon Lowry, MD, as the company’s medical director. Dr. Lowry brings to Zenas more than 20 years of extensive clinical expertise in the design and execution of early to late-stage clinical programs, where he will lead the company’s global clinical, medical affairs and pharmacovigilance functions.
“We are delighted to welcome Dr. Lowry to Zenas at this pivotal time for the company as we begin two registrational phase three trials for our lead product candidate, obexelimab, in the fourth quarter of this year and as we we are launching the first clinical trials in humans. for multiple pipeline programs,” said Hua Mu, medical doctor, doctorate, CEO of Zenas. “Dr. Lowry’s proven leadership, extensive clinical development experience and extensive global clinical trial experience will further strengthen our ability to execute on our mission to transform the lives of patients with unmet medical needs by providing the best immune therapies.
Dr. Simon Lowry added: “Many patients with autoimmune and rare diseases need new effective treatment options. Zenas’ deeply experienced and talented team has made impressive progress advancing the company’s pipeline in a very short time, and I look forward to leading the continued advancement of Zenas’ clinical programs through commercialization while expanding further the company’s pipeline of innovative programs.
Dr. Lowry is a physician with 20 years of experience in large emerging pharmaceutical and biotechnology companies, leading successful development programs, leading clinical and medical affairs teams, and interacting with regulatory bodies in multiple areas of medicine. , including rheumatology, immunology and ophthalmology. . Prior to joining Zenas, Dr. Lowry was Medical Director at Kinevant Science, a clinical-stage biopharmaceutical company focused on the treatment of rare inflammatory and autoimmune diseases. Dr. Lowry was previously Head of Immunology R&D at Roivant Sciences, driving all development-stage immunology assets into clinical development, and was a key member of the management team. He also served as Medical Director at Sun Pharma North America, where he was responsible for four branded therapeutic areas (Immunology and Dermatology, Ophthalmology, Neurology and Oncology), and led all aspects of development and medical functions ( including clinical development, medical information, field medicine, HEOR, medical publications/communications and operations). Early in his career, he worked at Novartis, where he held the position of Vice President, Head of Global Medical Affairs Franchise, Immunology and Dermatology, and at Pfizer, where he held positions of increasing responsibility, notably as Vice President, Group Head of Medical Affairs in Oncology.
Prior to his pharmaceutical/biotechnology career, Dr. Lowry practiced internal medicine at various institutions in the UK and Australia. He received his BA from Trinity Hall, University of Cambridge, UK and his MB BChir MD from the University of Cambridge School of Clinical Medicine.
About Zenas BioPharma
Zenas BioPharma is a global biopharmaceutical company committed to becoming a leader in the development and commercialization of immune therapies for patients worldwide. With clinical development and operations in the United States and China, Zenas is rapidly advancing an extensive portfolio of innovative therapeutic products that continues to grow through our successful commercial development strategy. Our experienced leadership team and network of business partners drive operational excellence to deliver potentially transformative therapies to improve the lives of people facing autoimmune and rare diseases. For more information about Zenas BioPharma, please visit www.zenasbio.com and follow us on Twitter at @ZenasBioPharma and Linked